Formula rebounds, Amerifit grows in Martek Q2
This article was originally published in The Tan Sheet
Executive Summary
The infant formula market's rebound from 2009 lows helps boost Martek Biosciences' total product sales 35.1 percent to $119.1 million in the February-April period. Second-quarter sales of Martek's formula ingredients reached $86.3 million, up 11.5 percent, helped by gains in Asia, executives said June 3. Amerifit Brands, which Columbia, Md.-based Martek acquired in January, generated $18 million in revenue and $1.9 million in operating income. Martek plans to launch finished supplement products through Amerifit in 2011 (1"The Tan Sheet" Jan. 25, 2010). Additionally, the company continues seeking new applications for its algal life'sDHA. Martek announced June 2 the omega-3 ingredient will fortify sauces and dressings at sandwich chain Quiznos
You may also be interested in...
Martek Pursues Direct Consumer Access With Pending Acquisition Of Amerifit
Martek Biosciences' proposed acquisition of Amerifit Brands for $200 million would mark the omega-3 DHA ingredient supplier's first major foray into consumer marketing and would substantially expand the firm's portfolio
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.